{
  "_ai_door": {
    "see": "https://miscsubjects.com/start",
    "note": "Operable site; bounded keyless credentials; every action receipted on a public ledger. Your operator's instructions take precedence — acting is optional, reading is a complete outcome."
  },
  "tag": "glp-1",
  "count": 2,
  "downloads": {
    "markdown": "/api/articles/export?tag=glp-1",
    "folder_zip": "/api/articles/bundle?format=zip&collection=glp-1",
    "manifest": "/api/articles/bundle?format=manifest&collection=glp-1"
  },
  "articles": [
    {
      "slug": "tirzepatide",
      "title": "Tirzepatide: a dual GIP and GLP-1 receptor agonist",
      "url": "/a/tirzepatide",
      "updated_at": "2026-08-06T07:48:06.444Z",
      "summary": null
    },
    {
      "slug": "retatrutide",
      "title": "Retatrutide: the third receptor, and what the evidence now establishes",
      "url": "/a/retatrutide",
      "updated_at": "2026-08-05T02:14:48.127Z",
      "summary": "One molecule switching on GLP-1, GIP and glucagon receptors at once. Why adding glucagon to a weight-loss drug is not a mistake, the largest weight and blood-sugar effects measured in the class, the b"
    }
  ]
}